On Friday, a three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans issued a unanimous ruling that blocks the mailing of mifepristone, a medication used in over half of all U.S. abortions. This decision overturns recent FDA regulations that allowed the drug to be dispensed via mail and requires that it only be distributed in person at clinics. Below, we answer key questions about this ruling and its implications.
What exactly did the federal appeals court decide?
The 5th Circuit Court of Appeals ruled to restrict access to mifepristone by prohibiting its distribution through mail or courier services. The unanimous decision from the three-judge panel mandates that the abortion pill must be dispensed only in person at certified clinics or medical offices. This effectively reinstates pre-2021 restrictions that the FDA had eased during the pandemic to allow telemedicine prescriptions and mail delivery. The court argued that the FDA overstepped its authority in relaxing those rules, siding with a lawsuit brought by anti-abortion medical groups.
Why is this ruling significant for abortion access?
Mifepristone is a key component in medication abortion, which now accounts for more than half of all abortions in the United States. By blocking mail delivery, the ruling effectively reduces access for patients who rely on telemedicine or live far from clinics. This is especially impactful in states where abortion remains legal but clinic access is limited. The decision also creates legal uncertainty because the case may eventually reach the Supreme Court. Additionally, it conflicts with the FDA's own scientific assessment that mifepristone is safe for home use, raising broader questions about judicial interference in drug regulation.
How does the ruling change FDA regulations on mifepristone?
The FDA had modified its Risk Evaluation and Mitigation Strategy (REMS) for mifepristone in 2021 and 2023, removing the requirement for in-person dispensing. This allowed certified prescribers to prescribe the drug via telemedicine and mail it to patients. The appeals court ruling nullifies those changes, reverting to the earlier rule that only in-person dispensing is permitted. However, the court did not fully suspend the FDA's approval of mifepristone, as a lower court had attempted. The decision applies nationwide unless further legal action intervenes.
What is mifepristone and how is it used in abortion care?
Mifepristone, often sold under the brand name Mifeprex, is a drug that blocks the hormone progesterone, which is necessary for pregnancy to continue. When used in combination with another medication called misoprostol, it effectively terminates an early pregnancy (up to 10 weeks). The two-step process is over 95% effective and is considered safer than surgical abortion. Prior to the FDA regulatory changes, patients had to visit a clinic in person to receive mifepristone. The 2021 relaxation allowed for no-test telemedicine where a consultation by video could suffice, and the pills could be delivered by mail.
Who brought the lawsuit that led to this ruling?
The lawsuit was filed by a coalition of anti-abortion medical groups, including the American Association of Pro-Life Obstetricians and Gynecologists and the Christian Medical & Dental Associations. They argued that the FDA exceeded its authority when it relaxed restrictions on mifepristone in 2016 and later, especially regarding safety. The plaintiffs claimed that the drug was not adequately studied for home use and that allowing mail delivery posed risks to women. The case was originally heard by Judge Matthew Kacsmaryk in Texas, who issued a sweeping ruling that attempted to revoke the FDA's approval of mifepristone entirely. The 5th Circuit narrowed that but still blocked mail distribution.
What are the immediate practical effects on patients and providers?
Starting immediately after the ruling, patients can no longer receive mifepristone by mail. They must schedule an in-person visit to a clinic that is certified to dispense the drug. This places a burden on those in rural areas or states with few clinics. It also affects providers who had shifted to telemedicine models. However, the ruling does not affect the use of misoprostol alone (which is sometimes used off-label for abortion) or the surgical method. Some legal experts expect further appeals and potential emergency requests to the Supreme Court to stay the ruling while the case proceeds.
What happens next in the legal process?
The case will likely return to the district court for further proceedings, and an appeal to the full 5th Circuit or directly to the Supreme Court is expected. The Biden administration has indicated it will continue to defend the FDA's actions. Meanwhile, the ruling remains in effect unless a higher court issues a stay. The outcome could reshape medication abortion access nationwide, particularly if the Supreme Court weighs in. In the interim, some patients may turn to alternative medications or travel to states with less restrictive laws. Legal experts note that this case could set a precedent for how courts review FDA drug safety decisions.